Colonic inflammatory mediators

Colonic inflammatory mediators represent a broad and heterogeneous collection of signaling molecules, including cytokines, chemokines, and lipid-derived mediators, that regulate the inflammatory environment within the large intestine [3, 7]. These substances, such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and various prostaglandins, are secreted by resident immune cells, recruited leukocytes, and intestinal epithelial cells in response to stimuli [4, 15]. In healthy states, these mediators maintain a delicate balance to protect against pathogens while preventing excessive tissue damage; however, in diseases like Ulcerative Colitis and Crohn's Disease, this balance is disrupted, leading to chronic inflammation and mucosal injury [3, 6]. Pharmacological intervention typically involves targeting specific high-impact mediators or their signaling pathways to reduce inflammation and promote mucosal healing [6, 9, 14]. Because the term refers to a functional group of diverse molecules rather than a single protein or receptor, it is classified as a descriptive category rather than a specific therapeutic target [3, 9].

Other names

Pro-inflammatory cytokinesColonic cytokinesInflammatory markers of the colonIntestinal inflammatory mediatorsInflammatory milieu of the colon

Drugs targeting these mediators typically act by neutralizing specific pro-inflammatory cytokines (e.g., anti-TNF antibodies), blocking their respective receptors (e.g., IL-12/23 inhibitors), or inhibiting intracellular signaling cascades such as the Janus kinase (JAK)-STAT pathway that regulate the production and signaling of multiple mediators [3, 6, 9].